Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
About
- About Us
- FAQs
- Sponsors
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

Menu

Home
About
- About Us
- FAQs
- Sponsors
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

[denovo_breadcrumbs]

Key clinical interventions in T2DM – Kidney disease and diabetes

Questionnaire

To access this module, please register or login:

Login or Register

Time limit: 0

Questionnaire Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you have failed to achieve the 70% pass mark required by the accrediting HPCSA.

Please read/watch the module carefully and try once more! (Only two tries are allowed)

PLEASE NOTE: you will no longer receive a fail confirmation email.
Congratulations on successfully completing this FREE CPD module!

For HPCSA members only: No need to load your certificate on HPCSA, as deNovo Medica uploads these weekly. Please allow 5-10 working days for the CPD activity to reflect on your HPCSA profile.

For non-HPCSA members: The above button allows you to download and print your CPD certificate to submit to your council yourself.

PLEASE NOTE: you will no longer receive a pass confirmation email! Visit YOUR PROFILE to find all your CPD certificates and activities completed.

Review
Answered
Correct
Incorrect

Question 1 of 10

1. Question

1. Early screening for DKD enables early intervention to preserve renal function and protect against cardiovascular risk, morbidity and mortality

A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 2 of 10

2. Question

2. The causes of 60% of all kidney disease are:

A. Glomerulonephritis and hypertension
Correct Incorrect Correct answer

B. Diabetes and hypertension
Correct Incorrect Correct answer

C. Diabetes and glomerulonephritis
Correct Incorrect Correct answer

D. Glomerulonephritis, diabetes and hypertension
Correct Incorrect Correct answer
Question 3 of 10

3. Question

3. In PLWD, the risk for CVD is increased five-fold if:

A. Albuminuria is present
Correct Incorrect Correct answer

B. eGFR is impaired
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 4 of 10

4. Question

4. Non-specific clinical signs and symptoms of kidney disease include:

A. Bone or joint pain
Correct Incorrect Correct answer

B. Muscle cramps
Correct Incorrect Correct answer

C. Heartburn
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer
Question 5 of 10

5. Question

5. A single UACR and eGFR screening is adequate for staging the extent of kidney dysfunction.

A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 6 of 10

6. Question

6. For the patient with T2DM and who has or develops kidney disease, the KDIGO recommend early initiation of:

A. ACEi/ARB
Correct Incorrect Correct answer

B. GLP-1RA
Correct Incorrect Correct answer

C. SGLT2i
Correct Incorrect Correct answer

D. Nonsteroidal MRA
Correct Incorrect Correct answer
Question 7 of 10

7. Question

7. The EMPA-KIDNEY trial was discontinued early due to overwhelming evidence of empagliflozin efficacy for the primary outcome of kidney disease progression and cardiovascular death in patients with:

A. CKD and T2DM
Correct Incorrect Correct answer

B. CKD and without T2DM
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 8 of 10

8. Question

8. If hypoglycaemia occurs upon initiating SGLT2i in patients with T2DM who are currently using sulphonylurea or insulin therapy, consider:

A. Reducing the sulphonylurea dose
Correct Incorrect Correct answer

B. Discontinuing insulin
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 9 of 10

9. Question

9. The LEADER trial investigating the effects of liraglutide on renal outcomes in T2DM demonstrated benefit for:

A. Macroalbuminuria
Correct Incorrect Correct answer

B. Doubling of creatinine
Correct Incorrect Correct answer

C. Time to renal replacement therapy
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer
Question 10 of 10

10. Question

10. Prespecified pooled analysis of FIDELITY participants with CKD and T2DM has demonstrated that, compared with placebo, finerenone reduced the risk for:

A. CKD progression by 23%
Correct Incorrect Correct answer

B. Cardiovascular morbidity and mortality by 14%
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer

All Rights Reserved 2026 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?